Natriuretic Peptides as Biomarkers for Congestive States: The Cardiorenal Divergence

Table 1

Changes in natriuretic peptides in patients treated for acute heart failure.

First author (year)	Number of UF patients	Age (years)	Male gender (%)	Decrease in weight (Kg)	Fluid removed (liters)	Change in BNP; (pg/ml)	Change in Scr; (mg/dL)
Costanzo (2005) [29]	20	74.5	75	6	8.65	−442 at discharge	No significant change (+0.08 at discharge)
Costanzo (2007) [30]	100	62	70	5	4.6	NA (baseline 1256; similarly improved in both groups)	No significant change (+0.3 at 72 hours)
Giglioli (2011) [31]	15	72.4	87	5.43	9.3	−3266 at 36 hours (NT-proBNP)	No significant change (−0.55) at 36 hours
Hanna (2012) [32]	19	60	84.2	4.7	5.2	−2291 at 48 hours (NT-proBNP)	No significant change (+0.2) at 48 hours
Bart (2012) [33]	94	69 (median)	78	5.7	7.44	−814 at 96 hours (NT-proBNP)	+0.23 at 96 hours
Jefferies (2013) [34]	87 (HFLEF) 97(HFPEF)	65 (HFLEF) 67 (HFPEF)	64 (HFLEF) 46 (HFPEF)	7.57 (HFLEF) 6.39 (HFPEF)	11.14 (HFLEF) 10.6 (HFPEF)	−211 (HFLEF); −88 (HFPEF) at discharge	+0.22 (HFLEF); no significant change in HFPEF group (+0.9) at discharge
Costanzo (2016) [35]	110	67	69.1	10.7 at 72 hours	18.7	−250 at discharge	+0.12 at discharge

+ and − before a number indicate “increase by” and “decrease by,” respectively. Scr: serum creatinine; NA: not available; HFLEF: heart failure with low ejection fraction; HFPEF: heart failure with preserved ejection fraction; UF: ultrafiltration.